Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Uterine Cervical Neoplasms 1Small Cell Lung Carcinoma 1Resectable Non-small Cell Lung Cancer 1Ovarian Cancer Recurrent 1NSCLC 1Lymphatic Metastasis 1Esophageal Squamous Cell Carcinoma 1Carcinoma 1

Interventions

Drug Therapy 3Carboplatin 3Surgical Procedures, Operative 2Pemetrexed 2Paclitaxel 2Cisplatin 2toripalimab 1tislelizumab 1surufatinib 1osimertinib 1lorlatinib 1anlotinib 1aflutinib 1Radiotherapy 1Radiosurgery 1Platinum Compounds 1Neoadjuvant Therapy 1Diphenhydramine 1Cryotherapy 1Chemotherapy, Adjuvant 1Chemoradiotherapy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × NSCLC × Platinum Compounds × Clear all
NCT07358689 2026-01-22

Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
120 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡